Every 10-Q that Sana Biotechnology, Inc. (SANA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow SANA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SANA filings page.
Sana Biotechnology, Inc. is a development-stage cell therapy company with no approved products, focused on engineered cell medicines for type 1 diabetes and in vivo CAR-T therapies (SC451, SG293, SG227). For the six months ended June 30, 2026, it reported a net loss of $110.8 million, improved from $143.2 million in 2025, and an accumulated deficit of $2.0 billion.
Cash, cash equivalents, and marketable securities totaled $160.5 million, while net cash used in operating activities was $70.2 million, indicating high cash burn. Management states that current capital resources may not fund operations for 12 months and that there is substantial doubt about the company’s ability to continue as a going concern.
To bolster liquidity in 2026, Sana raised approximately $68.6 million via an at-the-market equity facility and about $25 million from a stock purchase agreement with Mayo Clinic, which also includes a collaboration and license arrangement. Additional capital may come from Mayo’s option to buy further shares and from up to $150.0 million of future ATM sales. The balance sheet also includes sizable fair-value liabilities for Cobalt acquisition contingent consideration of $150.8 million and success payment liabilities of $24.5 million.
Sana Biotechnology reported a Q1 2026 net loss of $47.2 million, slightly improved from $49.4 million a year earlier, driven by lower research and development spending. Research and development expenses fell to $28.7 million, partly from suspending certain allogeneic CAR T programs, while general and administrative costs held steady at $11.5 million.
Cash, cash equivalents, and marketable securities totaled $101.1 million as of March 31, 2026. Management concluded these resources may not fund operations for 12 months, creating “substantial doubt” about the company’s ability to continue as a going concern.
After quarter-end, Mayo Clinic purchased 7,507,507 shares at $3.33 per share for about $25.0 million, with an option to buy an additional 7,507,507 shares on the same terms. Sana also has an at-the-market facility allowing it to sell up to $150.0 million of common stock, though no shares were sold in Q1.
Sana Biotechnology reported Q3 2025 results, highlighting lower operating expenses and a narrower loss. Total operating expenses were $43.5 million, down from $61.8 million a year ago, driven by research and development of $30.1 million and general and administrative of $10.3 million. Net loss was $42.2 million (basic and diluted net loss per share $0.16), improving from $59.9 million in Q3 2024.
Cash, cash equivalents, and marketable securities totaled $153.1 million as of September 30, 2025. The company completed an August underwritten offering for net proceeds of approximately $80.6 million and sold 7.3 million shares under an ATM for $28.6 million in Q3. Management states existing liquidity, together with these proceeds, will fund planned operations for at least one year from the filing. For the first nine months, operating cash outflow was $111.2 million; results include a non-cash impairment of $44.6 million recognized in Q2 tied to facilities in Bothell and Seattle. Stockholders’ equity was $195.3 million. Shares outstanding were 266,366,120 as of October 29, 2025.
Sana Biotechnology reported continued development-stage losses and significant balance sheet changes through June 30, 2025. The company recorded a six-month net loss of $143.2 million and a three-month loss of $93.8 million, driven in part by a $44.6 million non-cash impairment of long-lived assets related to its Bothell and Seattle facilities. Total assets fell to $361.6 million from $501.0 million at year-end, and cash and cash equivalents declined to $71.3 million on the balance sheet. Long-term liabilities include $117.1 million of contingent consideration and $8.6 million of success payment liabilities tied to prior acquisitions and license agreements. Management completed an ATM facility and, subsequently, an underwritten offering that together provided additional net proceeds (including $70.0 million from the August offering and $28.6 million raised under the ATM after June 30), and believes available liquidity plus those proceeds will fund planned operations for at least one year. The company reported positive clinical signals for an investigator-sponsored islet transplant (UP421), including C-peptide production and PET-MRI evidence of engraftment, and announced portfolio prioritization toward T1D, B-cell autoimmune diseases, refractory B-cell malignancies, and the fusogen platform.